Clinical trials: Malignant Melanomas
Exudative Retinal Detachment and Uveal Melanoma
Dexamethasone Implant for Retinal Detachment in Uveal Melanoma
This is an investigator-initiated Phase I study of a single dose of an intravitreally-administered dexamethasone implant (Ozurdex™) in subjects with uveal melanomas (UM) and exudative retinal detachments (ERD: build-up of fluid…
- Trial name
- NCT04082962
- Testing
- Dexamethasone intravitreal implant
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Ivana K. Kim
Cutaneous Malignant Melanoma, Renal Cell Cancer
Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer
This is a pilot study of combination low dose rate brachytherapy (LDR) added to standard of care (SOC) immunotherapy in stage III and IV melanoma, stage IV renal call cancer, and stage IV urothelial cancer.
- Conditions
- Cutaneous Malignant Melanoma, Renal Cell Cancer, Urothelial Cancer of Renal Pelvis
- Trial name
- NCT04620603
- Testing
- Low Dose Rate Brachytherapy (LDR), Standard-of-Care Immunotherapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Case Comprehensive Cancer Center
Melanoma
Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma
It is a single-center,exploratory clinical trial aimed to evaluate the objective response rate (ORR) of Camrelizumab combined with apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma.
- Trial name
- NCT04397770
- Testing
- SHR1210, apatinib mesylate, Temozolomide Injection
- Volunteers
- 40 people
- Sponsor
- Peking University Cancer Hospital & Institute
Colorectal Neoplasms, Melanoma
A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
This study is intended to provide access to tremelimumab for patients who have previously received tremelimumab in a clinical trial.
- Conditions
- Colorectal Neoplasms, Melanoma, Prostatic Neoplasms, Renal Cell Carcinoma
- Trial name
- NCT00378482
- Testing
- CP-675,206 (Tremelimumab)
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 37 people
- Sponsor
- AstraZeneca
Malignant Melanomas
An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas
The goal of this clinical trial is provide new treatment for patients with advanced melanoma who have failed previous immunotherapy.
- Trial name
- NCT05928962
- Testing
- Recombinant Human Adenovirus Type 5 Injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Fujian Cancer Hospital
Melanoma and Vitiligo
Search for New Predictive Markers of the Immune Response in Vitiligo and Melanoma
Skin diseases can have various origins. However, a number of them are linked to an imbalance in the immune system which will lead to either an excessively strong autoimmune response or a complete lack of response against cancer…
- Trial name
- VITILIMEL (NCT04920162)
- Testing
- Biospecimen into patients who had skin diseases
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Advanced Solid Tumor
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors.
- Trial name
- NCT07749586
- Testing
- ARV-6723, Pembrolizumab, SOC
- Where
- 4 sites in United States
- Volunteers
- 499 people
- Sponsor
- Arvinas Inc.
Melanoma
To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma
This study is being conducted to explore the efficacy and safety of camrelizumab combined with SHR1020 in the treatment of advanced melanoma.
- Trial name
- NCT05051865
- Testing
- camrelizumab, SHR1020
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Cancer Hospital & Institute
Melanoma
EPO906 Therapy in Patients With Advanced Melanoma
This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause melanoma.
- Trial name
- NCT00035165
- Testing
- epothilone b
- Where
- 6 sites in United States
- Volunteers
- 51 people
- Sponsor
- Novartis Pharmaceuticals
Nevus, Seborrheic Keratosis (SK)
Impact of Skin Type on Wonud Healing and Scarring Following Facial Skin Surgery
The goal of this observational study is to learn how an individual's skin type influences the wound healing process and scar formation in Chinese patients undergoing facial dermatologic surgery.
- Conditions
- Nevus, Seborrheic Keratosis (SK), Cyst, Lipoma
- Trial name
- NCT07384299
- Where
- China
- Volunteers
- 173 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Advanced Cutaneous Melanoma
ITIL-168 in Advanced Melanoma
DELTA-1 is a phase 2 clinical trial to evaluate the efficacy and safety of ITIL-168 in adult subjects with advanced melanoma who have previously been treated with a PD-1 inhibitor.
- Trial name
- DELTA-1 (NCT05050006)
- Testing
- ITIL-168
- Where
- 22 sites in United States, Canada and 1 more
- Volunteers
- 29 people
- Sponsor
- Instil Bio
Melanoma
Minimally Invasive Groin Dissection for Melanoma
The purpose of this this study is to determine if a structured educational training program is successful in teaching surgeons a new operative technique. It will then be determined if this new operative technique is safe.
- Trial name
- SAFE-MILND (NCT01500304)
- Testing
- Minimally invasive inguinal lymph node dissection
- Where
- 11 sites in United States
- Volunteers
- 88 people
- Sponsor
- Mayo Clinic
Advanced Malignancies, Metastatic Cancer
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
- Trial name
- NCT03277352
- Testing
- INCAGN01876, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Biosciences International Sàrl
Metastatic Melanoma
Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma
In this randomized controlled phase III study the investigators will evaluate whether TIL infusion preceded by non-myeloablative chemotherapy and followed by high dose bolus interleukin-2 can result in an improved progression…
- Trial name
- TIL (NCT02278887)
- Testing
- Translational research, Cyclophosphamide, Fludarabine
- Where
- 2 sites in Denmark, Netherlands
- Volunteers
- 168 people
- Sponsor
- The Netherlands Cancer Institute
Melanoma, Advanced Melanoma
CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma
CMP-001-010 is a Phase 2 study of CMP-001 intratumoral (IT) and nivolumab intravenous (IV) administered to participants with refractory unresectable or metastatic melanoma.
- Conditions
- Melanoma, Advanced Melanoma, Metastatic Melanoma, Unresectable Melanoma
- Trial name
- NCT04698187
- Testing
- CMP-001, Nivolumab
- Where
- 25 sites in United States
- Volunteers
- 44 people
- Sponsor
- Regeneron Pharmaceuticals
Skin Cancer
A Pilot Study to Evaluate Optical Spectroscopy of Pigmented Skin Lesions
The incidence of malignant melanoma has increased dramatically in recent decades. In 1930, the lifetime risk of an individual in the United States developing melanoma was 1 in 1,500.
- Trial name
- NCT00633516
- Testing
- Optical Spectroscopy
- Where
- 2 sites in United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine
Melanoma, Non Small Cell Lung Cancer
Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies
Clinical study BCD-201-1 is a double-blind randomized study of the pharmacokinetics (PK), pharmacodynamics (PD), safety, and immunogenicity of BCD-201 versus Keytruda following intravenous administration to subjects with advanced…
- Trial name
- NCT05739006
- Testing
- BCD-201, Keytruda
- Where
- 3 sites in Russia
- Volunteers
- 131 people
- Sponsor
- Biocad
Melanoma
M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma
Previous studies suggests that M-Vax, a melanoma vaccine prepared from patients own cancer cells, can stimulated patients' immune system to react against their cancer.
- Trial name
- NCT00477906
- Testing
- M-Vax- autologous, hapten-modified melanoma vaccine
- Volunteers
- 387 people
- Sponsor
- AVAX Technologies
Malignant Melanoma, Melanoma
A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors
This study will test the safety of a drug called PF-08046031 in participants with melanoma and other solid tumors that have no current approved treatment or have spread through the body.
- Conditions
- Malignant Melanoma, Melanoma, Metastatic Melanoma, Solid Tumors
- Trial name
- NCT06799533
- Testing
- PF-08046031
- Where
- 11 sites in United States, France and 3 more
- Volunteers
- 11 people
- Sponsor
- Pfizer
Melanoma, Advanced Melanoma
MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.
Melanoma remains a common cancer with rising incidence, and despite significant improvements with immune checkpoint inhibitors (ICIs), clinical outcomes remain heterogeneous.
- Trial name
- NCT07574047
- Testing
- Immune Checkpoint Inhibitors
- Where
- 9 sites in Switzerland
- Volunteers
- 108 people
- Sponsor
- Swiss Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.